Lv2
110 积分 2025-08-18 加入
A multi-dimensional comparative study of 505(b)(2) NDAs approved by FDA and Class 2 NDAs approved by NMPA from 2017 to 2023: Uncovering trends, characteristics, and regulation of modified new drugs
7天前
已关闭
Patient-Reported Outcomes as Prognostic Indicators for Overall Survival in Cancer
3个月前
已完结
FDA’s New Plausible Mechanism Pathway
4个月前
已完结
Characterization of studies considered and required under Medicare’s coverage with evidence development program
4个月前
已完结
Navigating Pharmaceutical Patent Term Extension System in China
4个月前
已完结
Global Analysis of Regulatory Frameworks and Drug Safety Standards in the Drug Approval Process
6个月前
已完结
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
6个月前
已完结
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
6个月前
已完结
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
6个月前
已完结
Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs
6个月前
已完结
皖公网安备34019202002308
